The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
Paula Rodriguez Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, comments on the health-related quality of life (QoL) of patients with triple class-exposed (TCE) relapsed/refractory (R/R) multiple myeloma treated with idecabtagene vicleucel (ide-cel) versus standard regimens from the KarMMa-3 (NCT03651128) study. Overall, the study demonstrated a significant improvement in QoL measures in patients treated with ide-cel.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria from lectures: BMS, Janssen, Sanofi, GSK, Amgen, Regeneron and Takeda
Participation in Ad Board meetings: BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer and GSK
Consultant: BMS, Abbvie, Roche and Pfizer
Research funding: none
